Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

References

• Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi:10.1016/S0140-6736(18)32552-2
   PubMed Web of Science ®Google Scholar
• Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721–1731. doi:10.1016/S1470-2045(21)00531-3
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi:10.1056/NEJMoa1910962
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi:10.1056/NEJMoa1104390
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496. doi:10.1056/NEJMoa1103799
   PubMed Web of Science ®Google Scholar
• Lainé A, Sims TT, Le Saux O, Ray-Coquard I, Coleman RL. Treatment perspectives for ovarian cancer in Europe and the United States: initial therapy and platinum-sensitive recurrence after PARP Inhibitors or Bevacizumab Therapy. Curr Oncol Rep. 2021;23(12):148. doi:10.1007/s11912-021-01128-5
   PubMed Web of Science ®Google Scholar
• Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - A review. J Ovarian Res. 2019;12(1):103. doi:10.1186/s13048-019-0579-0
   PubMed Web of Science ®Google Scholar
• O’Malley DM. New therapies for ovarian cancer. J Natl Compr Canc Netw. 2019;17(5.5):619–621.
   PubMed Web of Science ®Google Scholar
• Pignata S, CCecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28:viii51–viii56. doi:10.1093/annonc/mdx441
   PubMed Web of Science ®Google Scholar
• Yondelis, trabectedin; 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis. Accessed May 25, 2024.
   Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107–3114. doi:10.1200/JCO.2009.25.4037
   PubMed Web of Science ®Google Scholar
• González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833–848. doi:10.1016/j.annonc.2023.07.011
   PubMed Web of Science ®Google Scholar
• Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth ovarian cancer consensus conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28(4):727–732.
   PubMed Web of Science ®Google Scholar
• Hurley LH, Zewail-Foote M. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv Exp Med Biol. 2001;500:289–299.
   PubMed Web of Science ®Google Scholar
• Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep. 2009;26(3):322–337. doi:10.1039/b808331m
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9(8):2157–2163. doi:10.1158/1535-7163.MCT-10-0263
   PubMed Web of Science ®Google Scholar
• Bonfanti M, La Valle E, Fernandez Sousa Faro JM, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 1999;14(3):179–186.
   PubMedGoogle Scholar
• Larsen AK, Galmarini CM, D’Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016;77(4):663–671. doi:10.1007/s00280-015-2918-1
   PubMed Web of Science ®Google Scholar
• Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001;92(4):583–588. doi:10.1002/ijc.1221
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7(8):961–966. doi:10.1038/91008
   PubMed Web of Science ®Google Scholar
• Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs. 2002;13(Suppl 1):S3–S6.
   PubMedGoogle Scholar
• Aune GJ, Takagi K, Sordet O, et al. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res. 2008;14(20):6449–6455. doi:10.1158/1078-0432.CCR-08-0730
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Crisafulli G, Giordano G, et al. PARP1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas-a preclinical and translational study. Cancers. 2021;13(24):6295. doi:10.3390/cancers13246295
   PubMed Web of Science ®Google Scholar
• Colmegna B, Uboldi S, Frapolli R, et al. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Br J Cancer. 2015;113(12):1687–1693. doi:10.1038/bjc.2015.407
   PubMed Web of Science ®Google Scholar
• Belgiovine C, D’Incalci M, Allavena P, Frapolli R. Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci. 2016;73(13):2411–2424. doi:10.1007/s00018-016-2166-5
   PubMed Web of Science ®Google Scholar
• Povo-Retana A, Landauro-Vera R, Alvarez-Lucena C, Cascante M, Boscá L. Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment-progresses in their use in combined cancer therapy. Molecules. 2024;29(2):331. doi:10.3390/molecules29020331
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70(6):2235–2244. doi:10.1158/0008-5472.CAN-09-2335
   PubMed Web of Science ®Google Scholar
• Coward JIG, Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev. 2012;23(6):333–342. doi:10.1016/j.cytogfr.2012.08.005
   PubMed Web of Science ®Google Scholar
• Cohen S, Bruchim I, Graiver D, et al. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med. 2013;91(3):357–368. doi:10.1007/s00109-012-0946-4
   PubMed Web of Science ®Google Scholar
• Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39–48. doi:10.1093/annonc/mdq352
   PubMed Web of Science ®Google Scholar
• Colombo N, Casado A, Fernandez C, Vergote I. Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): results from OVA-301 follow-up. J. Clin. Oncol. 32(5 Suppl.), Abstract 5551 (2014). Presented at: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO); 30 May–3 June; 2014; Chicago, IL, USA.
   Google Scholar
• Monk BJ, Ghatage P, Parekh T, et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol. 2015;26(5):914–920. doi:10.1093/annonc/mdv071
   PubMed Web of Science ®Google Scholar
• González Martín A. Safety profile of trabectedin in combination with liposomal pegylated doxorubicin in relapsed ovarian carcinoma: considerations for optimal management. Int J Gynecol Cancer. 2011;21(Suppl 1):S6–S8.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020;156(3):535–544. doi:10.1016/j.ygyno.2019.12.043
   PubMed Web of Science ®Google Scholar
• Colombo N, Gadducci A, Sehouli J, et al.; INOVATYON study group. INOVATYON/ ENGOT-ov5 study: randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6–12 months after last platinum line. Br J Cancer. 2023;128(8):1503–1513. doi:10.1038/s41416-022-02108-7
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Villanucci A, et al. A European, Observational, Prospective Trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive ovarian cancer. Oncologist. 2021;26(4):e658–e668. doi:10.1002/onco.13630
   PubMed Web of Science ®Google Scholar
• Davis A, Tinker AV, Friedlander M. Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624–631. doi:10.1016/j.ygyno.2014.02.038
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol. 2010;116(3):326–331. doi:10.1016/j.ygyno.2009.10.070
   PubMed Web of Science ®Google Scholar
• Gomez R, Harter P, Lück HJ, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer. 2009;19(7):1284–1287. doi:10.1111/IGC.0b013e3181a418ff
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17(4):1141. doi:10.1200/JCO.1999.17.4.1141
   PubMed Web of Science ®Google Scholar
• Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol. 2011;122(2):226–232. doi:10.1016/j.ygyno.2011.04.019
   PubMed Web of Science ®Google Scholar
• Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer. 2008;18(4):615–620. doi:10.1111/j.1525-1438.2007.01063.x
   PubMed Web of Science ®Google Scholar
• Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109(4):1072–1078. doi:10.1038/bjc.2013.389
   PubMed Web of Science ®Google Scholar
• McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8(1):10–16. doi:10.1158/1535-7163.MCT-08-0840
   PubMed Web of Science ®Google Scholar
• Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6(1):5. doi:10.1186/1471-2407-6-5
   PubMed Web of Science ®Google Scholar
• Frenel JS, Kim JW, Aryal N, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022;33(10):1021–1028. doi:10.1016/j.annonc.2022.06.011
   PubMed Web of Science ®Google Scholar
• Harter P, Mouret-Reynier MA, Lorusso D, et al. Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance. J Clin Oncol. 2023;41(16_suppl):5550. doi:10.1200/JCO.2023.41.16_suppl.5550
   PubMed Web of Science ®Google Scholar
• Turinetto M, Pignata S, Pisano C, et al. 45P MITO39: effiacy and tolerability of PLD-trabectedin in the treatment of relapsed ovarian cancer after maintenance therapy with PARP-i, a MITO observational case-control study. ESMO Open. 2023;8(1):100825. doi:10.1016/j.esmoop.2023.100825
   Google Scholar
• Vertechy L, Boccia SM, Tiberi G, et al. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study. Int J Gynecologic Cancer. 2023;33(2):243–249. doi:10.1136/ijgc-2022-003764
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Bologna A, et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, Mango, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J Clin Oncol. 2017;35(29):3347–3353. doi:10.1200/JCO.2017.73.4293
   PubMed Web of Science ®Google Scholar